- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06865105
능동적 건선 관절염을 가진 성인 참가자의 치료를위한 표적 요법 연구
2 단계 다기관, 무작위, 무작위, 플랫폼 플랫폼 연구는 능동적 건선 관절염을 가진 성인 대상의 치료를위한 표적 요법 연구
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms.
The therapies being assessed in this study are risankizumab, lutikizumab, ABBV-701, and ABBV-547. In Substudy 1, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. In Substudy 2, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: ABBV-701 monotherapy, risankizumab monotherapy, or a combination therapy of ABBV-701 and risankizumab. In Substudy 3, participants will be randomized in a 1:1:1 ratio to one of three doses of ABBV-547. Around 300 participants will be enrolled in the study at approximately 110 sites worldwide.
연구 개요
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: ABBVIE CALL CENTER
- 전화번호: 844-663-3742
- 이메일: abbvieclinicaltrials@abbvie.com
연구 장소
-
-
California
-
Huntington Beach, California, 미국, 92648-5994
- 모병
- Newport Huntington Medical Group /ID# 272764
-
연락하다:
- Site Coordinator
- 전화번호: 714-923-7112
-
-
Florida
-
Avon Park, Florida, 미국, 33825
- 모병
- Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 273085
-
연락하다:
- Site Coordinator
- 전화번호: 863-314-8555
-
Clearwater, Florida, 미국, 33765
- 모병
- Clinical Research Of West Florida - Phase I Unit /ID# 273198
-
Orlando, Florida, 미국, 32819
- 모병
- HMD Research LLC /ID# 273086
-
Tamarac, Florida, 미국, 33321
- 모병
- West Broward Rheumatology Associates /ID# 272892
-
Tampa, Florida, 미국, 33606
- 모병
- Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 273199
-
연락하다:
- Site Coordinator
- 전화번호: (813) 870-1292
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- 모병
- Northwestern Medicine - Northwestern Memorial Hospital /ID# 275469
-
Skokie, Illinois, 미국, 60076
- 완전한
- Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879
-
Willowbrook, Illinois, 미국, 60527
- 모병
- Willow Rheumatology and Wellness /ID# 277354
-
-
Maryland
-
Cumberland, Maryland, 미국, 21502
- 완전한
- Klein & Associates /ID# 272829
-
-
New Hampshire
-
Lebanon, New Hampshire, 미국, 03756
- 모병
- Dartmouth-Hitchcock Medical Center /ID# 272702
-
연락하다:
- Site Coordinator
- 전화번호: 603-650-4717
-
-
Ohio
-
Middleburg Heights, Ohio, 미국, 44130
- 모병
- Paramount Medical Research and Consulting /ID# 272757
-
-
Pennsylvania
-
Duncansville, Pennsylvania, 미국, 16635
- 모병
- Altoona Center For Clinical Research /ID# 272593
-
연락하다:
- Site Coordinator
- 전화번호: 814-296-6108
-
-
Tennessee
-
Memphis, Tennessee, 미국, 38119
- 모병
- Private Practice - Dr. Ramesh C. Gupta /ID# 272897
-
-
Texas
-
Austin, Texas, 미국, 78745
- 모병
- Tekton Research - West Gate /ID# 272765
-
Frisco, Texas, 미국, 75035
- 모병
- Arthritis and Rheumatology Research Institute - Frisco /ID# 277306
-
Houston, Texas, 미국, 77089-6142
- 모병
- Accurate Clinical Research - Houston /ID# 272754
-
San Antonio, Texas, 미국, 78251
- 모병
- Tekton Research, LLC /ID# 272901
-
Tomball, Texas, 미국, 77375
- 모병
- DM Clinical Research - Tomball /ID# 272760
-
-
-
-
-
Uherské Hradiště, 체코, 686 01
- 모병
- Medical Plus Research /ID# 272363
-
Zlín, 체코, 760 01
- 모병
- PV Medical Services /ID# 272368
-
-
Brno-mesto
-
Brno, Brno-mesto, 체코, 638 00
- 모병
- Revmatologie /ID# 272367
-
-
Moravian-Silesian Region
-
Hlučín, Moravian-Silesian Region, 체코, 748 01
- 모병
- L.K.N. Arthrocentrum /ID# 272366
-
-
-
-
Quebec
-
Sherbrooke, Quebec, 캐나다, J1G 2E8
- 모병
- Centre Hospitalier Universite De Sherbrooke - Hotel-Dieu Hospital /ID# 273715
-
Trois-Rivières, Quebec, 캐나다, G9A 3X2
- 모병
- Centre de Recherche Musculo-Squelettique /ID# 274397
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, 캐나다, S7H 0P4
- 모병
- Dr. Latha Naik Medical Professional Corporation /ID# 272803
-
-
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 폴란드, 85-068
- 모병
- Medicover Integrated Clinical Services - Bydgoszcz (SMO/Network/Consortium) /ID# 273297
-
-
Masovian Voivodeship
-
Pruszków, Masovian Voivodeship, 폴란드, 05-800
- 모병
- MCBK S.C. Iwona Czajkowska Anna Podrazka-Szczepaniak /ID# 273305
-
Warsaw, Masovian Voivodeship, 폴란드, 02-665
- 모병
- Centrum Medyczne Reuma Park /ID# 273301
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, 폴란드, 15-351
- 완전한
- Osteo Medic s.c. Artur Racewicz Jerzy Supronik /ID# 273304
-
-
Warmian-Masurian Voivodeship
-
Elblag, Warmian-Masurian Voivodeship, 폴란드, 82-300
- 완전한
- Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka /ID# 273306
-
-
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, 프랑스, 06001
- 모병
- Centre Hospitalier Universitaire de Nice - Hopital Pasteur /ID# 272771
-
-
Auvergne-Rhône-Alpes
-
Caluire-et-Cuire, Auvergne-Rhône-Alpes, 프랑스, 69300
- 모병
- Infirmerie Protestante De Lyon /ID# 273731
-
-
Indre-et-Loire
-
Chambray-lès-Tours, Indre-et-Loire, 프랑스, 37170
- 모병
- Centre Hospitalier Regional Universitaire De Tours - Hopital Trousseau /ID# 272762
-
-
Loiret
-
Orléans, Loiret, 프랑스, 45067
- 완전한
- Centre Hospitalier Regional d Orleans - Hopital de la Source /ID# 272877
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, 프랑스, 33076
- 완전한
- Chu Bordeaux - Hopital Pellegrin /ID# 273390
-
-
-
-
-
Budapest, 헝가리, 1027
- 모병
- Revita Reumatologiai Rendelo (Revita Kft.) /ID# 272857
-
Budapest, 헝가리, 1023
- 모병
- Semmelweis Egyetem Reumatologiai es Immunologiai Klinika /ID# 273195
-
-
Borsod-Abauj Zemplen county
-
Miskolc, Borsod-Abauj Zemplen county, 헝가리, 3529
- 모병
- Borsod-Abauj-Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktatokorhaz /ID# 272572
-
-
Fejér
-
Székesfehérvár, Fejér, 헝가리, 8000
- 모병
- Complex Rendelo Med Zrt. /ID# 272570
-
Veszprém, Fejér, 헝가리, 8200
- 모병
- Vital-Medicina /ID# 272855
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Participant is willing and able to comply with procedures required in the Master Protocol and relevant, actively enrolling substudies.
- Participant has a documented clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) at Screening Visit.
- Participant has active disease defined as greater than or equal to 3 tender joints (based on 68 joint count) and greater than or equal to 3 swollen joints (based on 66 joint count) at both the Screening Visit and Baseline Visit.
- Participant has active plaque PsO, with at least one psoriatic plaque of >= 2 cm diameter or nail changes consistent with PsO at Screening Visit.
- Participant must demonstrate intolerance or inadequate response to 1 to 2 targeted therapies (biologic or targeted synthetic disease-modifying antirheumatic drugs) approved for the treatment of PsA
Exclusion Criteria:
- Participants who have had major surgery performed within 12 weeks prior to randomization or plan to have a major surgery during conduct of the study (e.g., aneurysm removal, stomach ligation).
- Participants with the following active, chronic, or recurring infections: Are infected with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus(HCV) infection, active tuberculosis(TB)
- Active skin disease other than psoriasis (PsO) which could interfere with the assessment of PsO.
- History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than psoriatic arthritis (PsA) (including but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Substudy 1: Risankizumab Monotherapy
Participants will receive risankizumab |
Subcutaneous (SC) Injection |
|
실험적: Substudy 1: Lutikizumab Monotherapy
Participants will initially receive lutikizumab Dose A followed by Lutikizumab Dose B every other week. |
Subcutaneous (SC) Injection |
|
실험적: Substudy 1: Lutikizumab and Risankizumab Combination Therapy
Participants will be administered lutikizumab and risankizumab at the same time following the same dosing regimen as the monotherapy arms. |
Subcutaneous (SC) Injection Subcutaneous (SC) Injection |
|
실험적: Substudy 2: ABBV-701 Monotherapy
Participants will initially receive ABBV-701. |
Subcutaneous (SC) Injection |
|
실험적: Substudy 2: Risankizumab Monotherapy
Participants will receive risankizumab. |
Subcutaneous (SC) Injection |
|
실험적: Substudy 2: ABBV-701 and Risankizumab Combination Therapy
Participants will be administered ABBV-701 and risankizumab at the same time following the same dosing regimen as the monotherapy arms. |
Subcutaneous (SC) Injection Subcutaneous (SC) Injection |
|
실험적: Substudy 3: ABBV-547 Dose A
Participants will receive ABBV-547 Dose A. |
Subcutaneous (SC) Injection |
|
실험적: Substudy 3: ABBV-547 Dose B
Participants will receive ABBV-547 Dose B. |
Subcutaneous (SC) Injection |
|
실험적: Substudy 3: ABBV-547 Dose C
Participants will receive ABBV-547 Dose C. |
Subcutaneous (SC) Injection |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
기간: At Week 16
|
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria:
|
At Week 16
|
|
Number of Participants With Adverse Events (AEs)
기간: Up to Week 52
|
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Up to Week 52
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants Achieving Minimal Disease Activity (MDA) Response
기간: At Week 16
|
A participant was classified as achieving MDA if 5 of the following 7 criteria were met:
|
At Week 16
|
|
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
기간: At Week 16
|
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria:
|
At Week 16
|
|
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
기간: At Week 16
|
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:
|
At Week 16
|
|
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response (in the subset of participants with a PsO BSA ≥ 3% at Baseline)
기간: At Week 16
|
PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score, and was assessed in participants with Baseline psoriasis BSA involvement ≥ 3%. |
At Week 16
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: ABBVIE INC., AbbVie
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- M25-191
- 2024-519291-11 (Substudy 1) (기타 식별자: EU CT)
- 2026-525937-21 (Substudy 2) (기타 식별자: EU CT)
- 2026-527719-41 (Substudy 3) (기타 식별자: EU CT)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD 공유 기간
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD 공유 액세스 기준
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .